Introduction
Increased oxidative stress is well recognised in critically ill patients with systemic inflammatory response syndrome (SIRS). The increase in the production of toxic reactive oxygen species (ROS), and the depletion of endogenous protective antioxidant micronutrients are implicated in the initiation and continuation of critical illness.
This article examines the rationale and evidence for antioxidant trace element and vitamin micronutrient supplementation to combat aspects of oxidative stress associated with critical illness.
Oxidative Stress In Critical Illness
Critically ill patients are characterised by the presence of a general inflammatory process associated with any severe insult to the body, the systemic inflammatory response syndrome (SIRS). 1 These patients are at risk of increased oxidative stress ie "a state in which the level of toxic reactive oxygen species (ROS) overcomes the endogenous antioxidant defences of the host." 2 ROS, or free radicals, are produced via a number of different pathways in critical illness, but mainly by the activation of polymorphonuclear leucocytes and by the respiratory mitochondrial chain. 3 ROS include superoxide (O 2 -), hydrogen peroxide (H 2 O 2 ), and hydroxyl radical (OH -), all of which may lead to cellular damage. These cause injury by direct oxidative damage to cellular proteins, nucleic acids and induce a process of lipid peroxidation (resulting in cell wall damage).
ROS may also have a more systemic effect. By playing a role in cell signalling, ROS are thought to activate cytokine release from inflammatory cells, in particular leading to the production of nuclear factor B (NF-B) 2,3 which has been shown to mediate the activation of endotoxins and inflammatory cytokines. 4 In the normal physiological state, the host is able to manage and prevent the unwanted effects caused by ROS. This endogenous defence mechanism consists of a number of antioxidant molecules that are capable of deactivating ROS and neutralising their potentially harmful effects. Antioxidant molecules can be divided into two distinct groups, enzymatic and non-enzymatic.
Of the enzymatic molecules, superoxidase dismutase (SOD), catalase and glutathione peroxidase appear to be most significant, playing an essential role in the conversion of O 2 and H 2 O 2 to H 2 O. The activity of these enzymatic antioxidants requires a number of trace elements in order to work at their maximum efficiency. These nutritional cofactors include selenium, copper, zinc, manganese, and iron.
The presence of selenium is critical for the function of glutathione peroxidase, and also plays a role in controlling the production of tri-iodothyronine from thyroxine. 5 Non-enzymatic antioxidants include endogenous and exogenous molecules. It is the exogenous antioxidant vitamins that are most commonly discussed in the literature. These include the lipid-soluble vitamins (E and ␤-carotene), and the water-soluble vitamins (C and glutathione). Active vitamin E, also known as ␣-tocopherol, is capable of disrupting lipid peroxidisation of cell walls and essential cell signalling pathways initiated by ROS. 2, 6, 7 It also plays a role in the direct neutralisation of ROS. 2 Critically ill patients are characterised by early depression of serum levels of many antioxidants, with the endogenous defence mechanisms rapidly becoming overwhelmed by the excessive production of ROS. Investigators have shown low serum levels of ␣-tocopherol and vitamin C in critically ill patients with sepsis and acute respiratory distress syndrome (ARDS). [8] [9] [10] [11] [12] [13] [14] In SIRS, there is a redistribution of vitamins and trace elements from the circulating volume to tissues involved in inflammatory processes. 15 Some animal models have shown this to be the case, particularly in relation to selenium and zinc. 16, 17 Reduced levels of antioxidants may also be attributable to excess losses, with zinc, selenium, copper and thiamine all detectable in biological fluids lost during critical illness. These include inflammatory exudates from burns, 18 drain outputs from trauma, 19 and effluents from continuous veno-venous haemodiafiltration. 20 Finally, the dilutional effects associated with fluid resuscitation may have some impact on serum antioxidant levels.
Antioxidant Supplementation
Supplementation with exogenous antioxidants to restore the oxidant/ anti-oxidant balance in critically ill patients has been considered for a number of years. However, there are few large, randomised, interventional trials that have investigated the role of antioxidant supplementation in the critically ill.
Heyland et al 21 performed a meta-analysis of articles published between 1980 and December 2003, searching four bibliographic databases (MEDLINE, EMBASE, CINHAL, and the Cochrane Database of Systematic reviews). Search terms included "trace elements", "vitamins", "critical illness" and "intensive care". Studies excluded were primarily those that did not report clinically important endpoints and those that examined multiple nutrients in addition to trace elements and vitamins. Eleven original papers (886 patients) were included. With the exception of one study which included 770 patients, 22 others had small numbers of patients.
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The five main antioxidants that were investigated were the trace elements selenium, zinc and copper, and the vitamins C (ascorbic acid) and E (␣-tocopherol).
When the results of all 11 trials of 886 patients were aggregated, Heyland et al found that there was a statistically significant reduction in mortality associated with those patients who had received antioxidant supplementation (CI = 0.44 -0.97). In their subgroup analysis of the results, they found a statistically significant reduction in mortality associated with trials that only used single antioxidants (CI = 0.27 -0.98) when compared to those trials that used a combination of antioxidants. Furthermore, when the results of those trials, when using the parenteral route to supply antioxidants were aggregated, antioxidant use was also associated with a statistically significant reduction in mortality (CI = 0.34 -0.92).
Selenium
Of the eleven studies examined by Heyland, seven included the supplementation of selenium as an interventional strategy either alone, or combined with other antioxidants. [23] [24] [25] [26] [27] [28] [29] All seven of these studies (n = 186) demonstrated a trend towards a lower mortality, but this was not statistically significant. There was also a trend towards a lower mortality in those studies using higher than the median dose of selenium (500 -1,000 g/day) when compared to those studies using lower doses (< 500 g/day). Again these findings were not statistically significant.
Another systematic review performed by the Cochrane Collaboration concentrated on the effects of selenium supplementation in critical illness, and included ebselen supplementation (a selenium containing organic compound). 5 Primary outcome measures were mortality and infection rates. Seven articles published between 1997 and 2001 (n = 813) were reviewed. Three were multicentre Japanese trials of ebselen, [30] [31] [32] with the remaining four all single centre trials in Germany and Switzerland examining selenium alone. [24] [25] [26] [27] [28] A statistically significant difference in mortality in favour of selenium supplementation was lost once statistical heterogeneity of the data was taken into account. There was no significant difference in infection rates, days spent on a ventilator, or days spent in ICU.
A recent review article specifically looking at the benefits of selenium supplementation 3 has examined conclusions drawn from these meta-analyses. Currently there is insufficient evidence to recommend supplementation in all patients, despite the recognition that selenium plays an important role in immune response and tissue defence, and is commonly deplete in the critically ill. However, non-statistically significant trends towards improved survival seen after selenium supplementation have brought forward calls for further well-designed, high-powered studies. This recommendation has been highlighted by one recent double-blinded, randomised controlled trial by Angstwurm et al, 33 that included 238 patients with SIRS, sepsis, and septic shock. Patients in the experimental group received an intravenous bolus of 1 mg sodium selenite, followed by an intravenous infusion over 14 days, with the primary outcome measure being 28-day mortality. Results from the intention-to-treat-analysis did not show a statistically significant reduction in mortality. However, when a further 49 patients were excluded for either not fulfilling inclusion criteria or violating study protocol, 28-day mortality was significantly reduced. Conclusions drawn from these results were based on an underpowered analysis, and the authors did accept a larger trial would be needed to confirm their results.
Other Trace Elements
Of the eleven articles identified by Heyland et al, three trials included the use of the trace elements zinc and copper.
In two of these trials, both in burns patients, the interventional group received a combination of zinc, copper and selenium. [23] [24] [25] [26] [27] [28] [29] One trial demonstrated a significant reduction in rate of bronchopneumonia (p = 0.013), with a trend towards shorter hospital stay. 29 One trial examined zinc supplementation in sixty-eight ventilated patients with severe closed head injuries. 34 Patients in the treatment group received 12 mg zinc for 15 days, and were found to have significantly improved recovery of GCS at 28 days when compared to those not receiving zinc (p = 0.03). There was a non-statistically significant trend towards improved mortality in the treatment group. 34 It is debatable whether the improvement in GCS is of clinical relevance.
Vitamins
There were three articles selected by Heyland et al that focused on using antioxidant vitamins as a therapeutic intervention in critically ill patients.
All of these trials used a combination of Vitamins C and E, with one trial also using Vitamin A. The most recent of these, performed by Nathens et al, 22 was a large scale randomised controlled trial analysing the effects of Vitamin C (1000 mg IV 8hrly) and ␣-tocopherol (1000 IU 8hrly) in 301 general surgical and trauma patients. Primary outcome measures were rates of ARDS and/or pneumonia. Although there was no statistically significant difference in pulmonary morbidity between the two groups, there was a significant reduction in the risk of developing MOF in those patients receiving vitamins (p = 0.04). As with previous trials discussed, the results collected by Nathens et al also showed a trend towards lower mortality in the antioxidant treated group. However, it should be noted that of a cohort of 595 patients, there were only 11 deaths.
Another trial by Preiser et al 35 compared the effects of an enteral solution enriched with Vitamins A, C and E with a control solution in 37 critically ill patients for a period of 7 days. They demonstrated good absorption of ␣-tocopherol and ␤-carotene, along with increased resistance of low-density lipoproteins to experimental oxidative stress. However, there was no statistically significant difference in mortality or infectious complications between the two groups.
When Heyland's group aggregated the results of non-selenium antioxidants (including Vitamins A, C and E), they found there was no significant effect on mortality or infectious complications.
Discussion
In critical illness, oxidative stress occurs by a combination of increased ROS production, and depression of endogenous antioxidant levels. The significance of increased oxidative stress in the development of complications of critical illness such ARDS and MOF has been suggested by many authors. This has led to the approach of antioxidant supplementation as a method to address the oxidant/ anti-oxidant imbalance that occurs during critical illness.
Heyland et al's meta-analysis based on eleven trials of 886 patients did find statistically significant reductions in mortality once results were aggregated. However on an individual basis, none of the trials included in their meta-analysis demonstrated a significant difference in mortality. These findings appear to be confusing, and may be explained by the general complexities of meta-analysis and the consequences of including one large trial amongst ten significantly smaller trials. There are also many difficulties inherent in studying a heterogeneous population, specifically in the ICU setting. Of importance, however, is that supplementation with trace elements and vitamins is not associated with an increase in deleterious side effects, and it is therefore tempting to regard the practice as safe.
If the general consensus is that antioxidant supplementation is safe, a logical intervention by virtue of its hypothesised antioxidant function(s), and effective to some extent, a number of further issues arise. Firstly, what is the optimal antioxidant supplementation regimen for critically ill patients?
On the basis of Heyland's meta-analysis, the evidence shows that antioxidants should be given parenterally, and as a single agent. There was also a non-significant trend suggesting that selenium is the most effective antioxidant. However, this was not confirmed by the recent Cochrane review looking specifically at selenium supplementation 5 which concluded that use should be restricted to clinical trials only.
Secondly, further work is required to determine when is the best time to initiate treatment and for how long to continue it. Antioxidants do not have the ability to repair damage already done by oxidative stress and their use should be thought of as prophylactic and as a result it is logical to initiate supplementation early.
Thirdly, what doses should be used? Although it has been suggested that higher doses of antioxidants have attributed to greater treatment effects, in vitro trials have shown that high doses of selenium, vitamin C and E are pro-oxidant. 15 Finally, the evidence is that the parenteral route should be used. However some anti-oxidant supplementation does not come in a suitable preparation (e.g. Vitamin E), and other potential anti-oxidants also have logistical challenges. 2 In conclusion, the evidence reviewed does suggest a role for anti-oxidant therapy in the management of critically ill patients. However, more large controlled randomised trials are required to define optimal management strategies.
